EKO International Corp.

EKO International Corp., through its joint venture interest in NeuroVasc Clinical Inc., promotes and distributes frequency rhythmic electrical modulation system equipment used in the treatment of peripheral neuropathy in Canada. The company, through its joint venture interest in NeuroVasc Clinical Inc., also sets up and/or manage clinics to treat patients using FREMSTM equipment. EKO International Corp. is based in Burlington, Canada.

EKO International Corp. trades as EKNL on OTC. The company is classified in Industrials / Conglomerates and reports in USD.

The current profile places the business in Conglomerates. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $0 of revenue and -$801,504 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

EKO International Corp. can be compared against peers such as A-Sonic Aerospace Limited, BrewBilt Manufacturing Inc., County Line Energy Corp., Delphax Technologies Inc., Green Energy Enterprises, Inc., JPX Global, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $3,168, beta of 7.77, and return on equity of +29.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

EKNL currently shows total debt of $589,298 and beta of 7.77. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.ekointl.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.